首页 > 最新文献

BJU International最新文献

英文 中文
Response to utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations. 在儿科肾盂成形术中使用肾长度差异指数的应对措施:临床应用和注意事项。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16510
Ketaki Gharpure, Abraham Cherian
{"title":"Response to utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations.","authors":"Ketaki Gharpure, Abraham Cherian","doi":"10.1111/bju.16510","DOIUrl":"https://doi.org/10.1111/bju.16510","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inheritance patterns of lower urinary tract symptoms in adults: a systematic review. 成人下尿路症状的遗传模式:系统综述。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16517
Lorcan Moore, Nicholas Raison, Sachin Malde, Prokar Dasgupta, Arun Sahai

Objective: To compile and evaluate the heritability and inheritance patterns of lower urinary tract symptoms (LUTS) in adult cohorts.

Methods: Searches of five databases (PubMed, Embase, APA PsycInfo, Global Health, and OVID Medline) commenced on 6 July 2024, resulting in 736 articles retrieved after deduplication. Studies evaluating heritability patterns, gene frequencies, and familial aggregation of symptoms were included for review. Screening and predefined eligibility criteria produced 34 studies for final review. A descriptive analysis of synthesised data was performed, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The Cochrane Risk of Bias in Non-Randomised Studies of Interventions (ROBINS-I) tool and the Johanna Briggs Institute checklist were used to evaluate these studies.

Results: Ten of the 34 studies (29%) described general LUTS, 14 (41%) described symptoms due to benign prostatic enlargement (BPE), nine (26%) described urinary incontinence (UI; urge UI [UUI], stress UI [SUI] and mixed UI [MUI]), four (12%) described nocturia alone, two (6%) described overactive bladder (OAB), and four (13%) described other specific symptoms (frequency, postvoid residual urine volume). BPE symptoms, UI (MUI and UUI), nocturia alone, and frequency alone were associated with genetic predisposition, whilst OAB and SUI had more modest inheritance.

Conclusion: The pathogenetic and pharmacological mechanisms fundamental to LUTS manifestation are highly heterogeneous. Further work is required to evaluate the inheritance patterns of LUTS more extensively.

目的汇编并评估成人队列中下尿路症状(LUTS)的遗传率和遗传模式:从 2024 年 7 月 6 日开始对五个数据库(PubMed、Embase、APA PsycInfo、Global Health 和 OVID Medline)进行检索,经过重复数据删除后共检索到 736 篇文章。对遗传模式、基因频率和症状的家族聚集性进行评估的研究被纳入审查范围。通过筛选和预先确定的资格标准,最终有 34 项研究被纳入审查范围。根据《系统综述和元分析首选报告项目》指南,对综合数据进行了描述性分析。评估这些研究时使用了 Cochrane 非随机干预研究中的偏倚风险(ROBINS-I)工具和约翰娜-布里格斯研究所核对表:34项研究中有10项(29%)描述了一般LUTS,14项(41%)描述了良性前列腺增生(BPE)引起的症状,9项(26%)描述了尿失禁(UI;急迫性尿失禁[UUI]、压力性尿失禁[SUI]和混合性尿失禁[MUI]),4项(12%)描述了单纯夜尿,2项(6%)描述了膀胱过度活动症(OAB),4项(13%)描述了其他特殊症状(尿频、排尿后残余尿量)。BPE 症状、UI(MUI 和 UUI)、单纯夜尿和单纯尿频与遗传易感性有关,而 OAB 和 SUI 的遗传性较弱:结论:导致尿失禁的基本病理和药理机制存在很大差异。结论:尿路结石表现的基本病理机制和药物机制具有高度异质性,需要进一步开展工作,更广泛地评估尿路结石的遗传模式。
{"title":"Inheritance patterns of lower urinary tract symptoms in adults: a systematic review.","authors":"Lorcan Moore, Nicholas Raison, Sachin Malde, Prokar Dasgupta, Arun Sahai","doi":"10.1111/bju.16517","DOIUrl":"https://doi.org/10.1111/bju.16517","url":null,"abstract":"<p><strong>Objective: </strong>To compile and evaluate the heritability and inheritance patterns of lower urinary tract symptoms (LUTS) in adult cohorts.</p><p><strong>Methods: </strong>Searches of five databases (PubMed, Embase, APA PsycInfo, Global Health, and OVID Medline) commenced on 6 July 2024, resulting in 736 articles retrieved after deduplication. Studies evaluating heritability patterns, gene frequencies, and familial aggregation of symptoms were included for review. Screening and predefined eligibility criteria produced 34 studies for final review. A descriptive analysis of synthesised data was performed, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The Cochrane Risk of Bias in Non-Randomised Studies of Interventions (ROBINS-I) tool and the Johanna Briggs Institute checklist were used to evaluate these studies.</p><p><strong>Results: </strong>Ten of the 34 studies (29%) described general LUTS, 14 (41%) described symptoms due to benign prostatic enlargement (BPE), nine (26%) described urinary incontinence (UI; urge UI [UUI], stress UI [SUI] and mixed UI [MUI]), four (12%) described nocturia alone, two (6%) described overactive bladder (OAB), and four (13%) described other specific symptoms (frequency, postvoid residual urine volume). BPE symptoms, UI (MUI and UUI), nocturia alone, and frequency alone were associated with genetic predisposition, whilst OAB and SUI had more modest inheritance.</p><p><strong>Conclusion: </strong>The pathogenetic and pharmacological mechanisms fundamental to LUTS manifestation are highly heterogeneous. Further work is required to evaluate the inheritance patterns of LUTS more extensively.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
September's reviewers of the month 九月份的月度评论员
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16498
{"title":"September's reviewers of the month","authors":"","doi":"10.1111/bju.16498","DOIUrl":"https://doi.org/10.1111/bju.16498","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142077820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. 原发性肾癌热消融术后的挽救性立体定向消融体放射治疗。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16520
Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor, Daniel G Schep, Michael Huo, Maggie Stein, Anand Swaminath, Raquibul Hannan, Shankar Siva

Objective: To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA).

Materials and methods: This study was a multi-institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer-specific survival (CSS), overall survival (OS), treatment-related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan-Meier method was used to estimate freedom from local and distant failure, CSS and OS.

Results: Seventeen patients with 18 biopsy-confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6-68.7) years, a median (IQR) tumour size of 3.5 (1.9-4.1) cm and follow-up (reverse Kaplan-Meier method) of 3.36 (95% confidence interval [CI] 1.6-4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5-5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression-free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%-100%), 92.3% (95% CI 78.9%-100%) and 82.1% (95% CI 62.1%-100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40-71) mL/min, and at last follow-up, it was 48 (33-57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end-stage renal disease.

Conclusion: The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.

摘要评估热消融(TA)后复发肾细胞癌(RCC)的挽救性立体定向消融体放疗(SABR)的有效性和安全性:本研究是一项多机构回顾性分析,研究对象为2016年至2020年间接受SABR治疗的TA后复发RCC患者。主要研究结果为无局部失败,根据实体瘤反应评估标准(RECIST)v1.1进行放射学评估。远处失败、癌症特异性生存率(CSS)、总生存率(OS)、治疗相关毒性和SABR后的肾功能变化是次要结果。采用 Kaplan-Meier 法估算局部和远处失败、CSS 和 OS 的自由度:17名患者中有18名经活检确诊为RCC,SABR时的中位(四分位距[IQR])年龄为75.2(72.6-68.7)岁,中位(IQR)肿瘤大小为3.5(1.9-4.1)厘米,随访(反向卡普兰-梅耶法)时间为3.36(95%置信区间[CI]1.6-4.1)年。17 名患者中有 6 名是单肾患者。五名患者在 SABR 之前重复 TA 失败。从TA手术到SABR的中位(IQR)时间为3.03(1.5-5.1)年。没有患者出现局部进展,局部控制率为 100%。四名患者出现远处进展,其中两名患者有基线转移性疾病。3年的无远处进展生存率、CSS和OS分别为72.1%(95% CI 51.9%-100%)、92.3%(95% CI 78.9%-100%)和82.1%(95% CI 62.1%-100%)。SABR前的肾小球滤过率中位数(IQR)为58(40-71)毫升/分钟,最后一次随访时为48(33-57)毫升/分钟。没有患者出现 3+ 级毒性或发展为终末期肾病:结果表明,SABR似乎是治疗TA后复发RCC患者的一种有效而安全的挽救策略。
{"title":"Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.","authors":"Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor, Daniel G Schep, Michael Huo, Maggie Stein, Anand Swaminath, Raquibul Hannan, Shankar Siva","doi":"10.1111/bju.16520","DOIUrl":"10.1111/bju.16520","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA).</p><p><strong>Materials and methods: </strong>This study was a multi-institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer-specific survival (CSS), overall survival (OS), treatment-related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan-Meier method was used to estimate freedom from local and distant failure, CSS and OS.</p><p><strong>Results: </strong>Seventeen patients with 18 biopsy-confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6-68.7) years, a median (IQR) tumour size of 3.5 (1.9-4.1) cm and follow-up (reverse Kaplan-Meier method) of 3.36 (95% confidence interval [CI] 1.6-4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5-5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression-free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%-100%), 92.3% (95% CI 78.9%-100%) and 82.1% (95% CI 62.1%-100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40-71) mL/min, and at last follow-up, it was 48 (33-57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end-stage renal disease.</p><p><strong>Conclusion: </strong>The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs 检测和治疗前列腺癌的进展加上预防复发性尿道炎的 d-甘露糖。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16499
{"title":"Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs","authors":"","doi":"10.1111/bju.16499","DOIUrl":"10.1111/bju.16499","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations. 在儿科肾盂成形术中使用肾长度差异指数:临床应用和注意事项。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16512
Jiayi Li, Weiping Zhang
{"title":"Utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations.","authors":"Jiayi Li, Weiping Zhang","doi":"10.1111/bju.16512","DOIUrl":"https://doi.org/10.1111/bju.16512","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of the Victo™ adjustable artificial urinary sphincter in the treatment of male incontinence. Victo™ 可调节人工尿道括约肌治疗男性尿失禁的效果。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-26 DOI: 10.1111/bju.16511
Jan Krhut, Lucie Bartáková, Adéla Kondé, Radek Paus Sýkora, Tomáš Rychlý, Roman Zachoval

Objectives: To report the clinical outcomes of the Victo™ (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery.

Patients and methods: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes.

Results: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period.

Conclusion: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.

目的报告在前列腺手术后严重尿失禁(UI)患者队列中植入 Victo™(阿根廷科尔多瓦 Promedon 公司)可调式人工尿道括约肌(AUS)的临床效果:本研究招募了在 2018 年 5 月至 2023 年 12 月期间接受 Victo 植入手术的前列腺术后尿失禁患者。对患者进行了基线、设备激活后 3 个月和 12 个月的前瞻性评估,此后每年进行一次评估。24小时尿垫重量测试(24hPWT)用于评估尿失禁的严重程度,而患者全球改善印象(PGI-I)和患者满意度则根据李克特量表来衡量患者报告的结果:最终分析共纳入96名患者,中位数(四分位数间距[IQR])年龄为68(65-72)岁。随访时间中位数(IQR)为 3(1-4)年。共有 10 名患者完成了为期 5 年的随访。治疗后,我们观察到 24hPWT 显著降低,中位数降低了 83%(P 结论:治疗后,24hPWT 显著降低,中位数降低了 83%):总之,我们的数据表明,Victo AUS 能明显减轻前列腺手术后尿频尿急的严重程度,并且在中期随访中,患者对治疗结果的满意度相当高。
{"title":"Outcomes of the Victo™ adjustable artificial urinary sphincter in the treatment of male incontinence.","authors":"Jan Krhut, Lucie Bartáková, Adéla Kondé, Radek Paus Sýkora, Tomáš Rychlý, Roman Zachoval","doi":"10.1111/bju.16511","DOIUrl":"https://doi.org/10.1111/bju.16511","url":null,"abstract":"<p><strong>Objectives: </strong>To report the clinical outcomes of the Victo™ (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery.</p><p><strong>Patients and methods: </strong>This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes.</p><p><strong>Results: </strong>A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period.</p><p><strong>Conclusion: </strong>In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. 对卡介苗无反应的非肌层浸润性膀胱癌,保膀胱疗法与根治性膀胱切除术的长期疗效对比。
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-25 DOI: 10.1111/bju.16509
Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey Howard, Wei Shen Tan, Ian McElree, Facundo Davaro, Kendrick Yim, Stephen Harrington, Elizabeth Dyer, Anna J Black, Pratik Kanabur, Mathieu Roumiguié, Seth Lerner, Peter C Black, Jay D Raman, Mark A Preston, Gary Steinberg, William Huang, Roger Li, Vignesh T Packiam, Solomon L Woldu, Yair Lotan

Objective: To quantify the oncological risks of bladder-sparing therapy (BST) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC).

Patients and methods: Pre-specified data elements were collected from retrospective cohorts of patients with BCG-unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG-unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re-resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials.

Results: Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow-up was 50 (20-69) months. There were no statistically significant differences in metastasis-free survival, cancer-specific survival, or overall survival between treatment groups. In the BST group, high-grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).

Conclusion: In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.

目的量化对卡介苗(BCG)无反应的非肌层浸润性膀胱癌(NMIBC)患者进行膀胱保留治疗(BST)与前期根治性膀胱切除术(RC)相比的肿瘤风险:从10个国际研究机构的卡介苗(BCG)无反应性非肌层浸润性膀胱癌(NMIBC)患者回顾性队列中收集了预先指定的数据元素。经机构审查委员会批准后,符合美国食品和药物管理局标准的卡介苗无反应NMIBC患者被纳入研究范围。收集了前期 RC 或 BST 后的肿瘤学结果。BST方案包括再次切除或仅监测、重复卡介苗、膀胱内化疗、全身免疫疗法和临床试验:在578名患者中,28%接受了前期RC,72%接受了BST。随访中位数(四分位数间距)为 50(20-69)个月。不同治疗组的无转移生存率、癌症特异性生存率和总生存率无明显统计学差异。在 BST 组中,12 个月和 24 个月的高级别复发率分别为 37% 和 52%,12 个月和 24 个月的 MIBC 进展率分别为 7% 和 13%。BST组中有31.7%的患者接受了RC治疗,13%的患者发现了结节病,而前期RC治疗中仅有4%的患者发现了结节病(P = 0.030):结论:在选定的患者群体中,初始 BST 的中期生存效果与前期 RC 相当。随着时间的推移,复发率和病情进展率会增加,特别是在接受了更多线 BST 治疗的患者中。
{"title":"Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.","authors":"Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey Howard, Wei Shen Tan, Ian McElree, Facundo Davaro, Kendrick Yim, Stephen Harrington, Elizabeth Dyer, Anna J Black, Pratik Kanabur, Mathieu Roumiguié, Seth Lerner, Peter C Black, Jay D Raman, Mark A Preston, Gary Steinberg, William Huang, Roger Li, Vignesh T Packiam, Solomon L Woldu, Yair Lotan","doi":"10.1111/bju.16509","DOIUrl":"10.1111/bju.16509","url":null,"abstract":"<p><strong>Objective: </strong>To quantify the oncological risks of bladder-sparing therapy (BST) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC).</p><p><strong>Patients and methods: </strong>Pre-specified data elements were collected from retrospective cohorts of patients with BCG-unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG-unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re-resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials.</p><p><strong>Results: </strong>Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow-up was 50 (20-69) months. There were no statistically significant differences in metastasis-free survival, cancer-specific survival, or overall survival between treatment groups. In the BST group, high-grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).</p><p><strong>Conclusion: </strong>In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New diabetic agents providing a glucose feast for urinary yeast - what to do? 新型糖尿病药剂为尿液酵母菌提供葡萄糖盛宴--怎么办?
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-19 DOI: 10.1111/bju.16480
Gordon Chen, Andrew A Mahony, Janelle Brennan, Gemma K Reynolds, Victoria G Hall
{"title":"New diabetic agents providing a glucose feast for urinary yeast - what to do?","authors":"Gordon Chen, Andrew A Mahony, Janelle Brennan, Gemma K Reynolds, Victoria G Hall","doi":"10.1111/bju.16480","DOIUrl":"https://doi.org/10.1111/bju.16480","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population-based prostate cancer outcomes registries - what have we learned and where are we heading? 基于人群的前列腺癌结果登记--我们学到了什么?
IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-19 DOI: 10.1111/bju.16487
Wee Loon Ong, Krupa Krishnaprasad, Jonathan Bensley, Michelle Steeper, Kerri Beckmann, Sibilah Breen, Michelle King, Stephen Mark, Michael O'Callaghan, Manish Patel, Emma Tod, Jeremy Millar
{"title":"Population-based prostate cancer outcomes registries - what have we learned and where are we heading?","authors":"Wee Loon Ong, Krupa Krishnaprasad, Jonathan Bensley, Michelle Steeper, Kerri Beckmann, Sibilah Breen, Michelle King, Stephen Mark, Michael O'Callaghan, Manish Patel, Emma Tod, Jeremy Millar","doi":"10.1111/bju.16487","DOIUrl":"https://doi.org/10.1111/bju.16487","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BJU International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1